Ray Therapeutics

Ray Therapeutics is focused on developing innovative gene therapies for the treatment of blinding retinal diseases. Their approach utilizes optogenetics, a revolutionary technology that uses light to control cells. Ray Therapeutics is developing gene therapies for RP, a progressive retinal disease that leads to blindness. They are also exploring the potential of their technology for treating other blinding retinal diseases. Their lead product, RTx-015, is a gene therapy candidate for the treatment of RP, designed to restore visual function by introducing light-sensitive proteins into retinal cells.

Jobs: